ACR Convergence

WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…

“What we’re after here is something called active allyship,” said Dr. Dwinita Mosby Tyler, CEO and founder of The Equity Project in her keynote address at ACR Convergence 2024. “It’s where you witness something that might be an injustice or you might see a disparity, and you don’t just talk about it, you research it; you do something about it.” 

WASHINGTON, D.C.—Retroperitoneal fibrosis (RPF) is often a challenging diagnosis to make, given a lack of serologic biomarkers and often difficulty in accessing tissue for biopsy, especially in cases confined to the retroperitoneum. The topic of retroperitoneal fibrosis was discussed during the CARE to Test Your Knowledge: Retroperitoneal Fibrosis session at ACR Convergence 2024. John Stone,…

The Voice of Rheumatology (VOR) Coalition convened last month at ACR Convergence 2024 in Washington, D.C., to discuss the pressing federal and state legislative priorities that will affect both the practice of rheumatology and patient care in the year ahead. The Coalition, composed of leading rheumatology professional societies and patient advocacy groups, gathered to examine…

WASHINGTON, D.C.—For the first time in U.S. history, older adults are projected to outnumber children by 2034, and their care poses unique challenges to the rheumatologist.1 Normal physiologic changes of aging include but aren’t limited to falling renal function, changes in pharmacokinetics and bone density loss. At the ACR Convergence 2024 Review Course, Namrata Singh,…

WASHINGTON, D.C.—Behçet’s disease (BD) is not a common condition, but we frequently receive referrals to evaluate for it in rheumatology clinics because a patient has oral or genital ulcers. So what’s Behçet’s and what’s not? How can we tell the difference? At the ACR Convergence 2024 Review Course, Johannes Nowatzky, MD, director, New York University…

At a Great Debate session, speakers discussed whether mixed connective tissue disease is a distinct disease entity in rheumatology.

At this ACR Convergence 2024 session, experts discussed new and creative ways to design trials to account for real-world scenarios and to produce information relevant to practicing clinicians.

At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.

A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.